LTCC is involved in regulation of the Zn wave.

(A) The intracellular labile Zn level after FcεRI-mediated stimulation was examined using the fluorescent Zn indicator Newport Green in mast cells with or without pre-treatment with 100 µM Verapamil, an LTCC antagonist. The data represent the relative fluorescent intensity of Newport Green. The difference in Newport Green intensity at 15 min between the control and Verapamil-treated BMMCs was statistically significant. *P<0.05, Student’s t-test. (B) The FcεRI-mediated Ca2+ elevation in control and Verapamil-treated BMMCs was examined using the fluorescent Ca2+ indicator Fluo-4. Data represent the relative fluorescent intensity of Fluo-4. The difference in Fluo-4 intensity between the control and Verapamil-treated BMMCs was not statistically significant. (C) The intracellular labile Zn level upon treatment with the LTCC agonist (s)-(-)-BayK8644 in BMMCs with or without 100 µM Verapamil. The difference in Newport Green intensity at 15 min between the control and Verapamil-treated BMMCs was statistically significant. ***P<0.001. (D) The intracellular labile Zn level upon (s)-(-)-BayK8644 treatment of BMMCs in control or Ca2+-free Tyrode’s buffer. The difference in Fluo-4 intensity between the control and Ca2+-free Tyrode’s buffer samples was not statistically significant. All data are representative of at least three experiments, and are shown as the mean + SEM. NPG, Newport Green; Vera, Verapamil; Bay, (s)-(-)-BayK8644.